As of June 21, 2025, Strongbridge Biopharma plc (SBBP) reports a Gross Margin of 92.81%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of Strongbridge Biopharma plc's Gross Margin
Over recent years, Strongbridge Biopharma plc's Gross Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2020-12-31 | 92.81% |
| 2019-12-31 | 82.40% |
| 2018-12-31 | 77.87% |
| 2017-12-31 | 78.87% |
This slight upward trend highlights how Strongbridge Biopharma plc manages its operational efficiency and pricing power over time.
Comparing Strongbridge Biopharma plc's Gross Margin to Peers
To better understand Strongbridge Biopharma plc's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Strongbridge Biopharma plc (SBBP) | 92.81% |
| Royalty Pharma PLC (RPRX) | 7775.20% |
| SCYNEXIS Inc (SCYX) | 100.00% |
| SOL Global Investments Corp (SOL.CN) | 96.92% |
| Chiasma Inc (CHMA) | 94.59% |
| Jaguar Health Inc (JAGX) | 83.27% |
Compared to its competitors, Strongbridge Biopharma plc's Gross Margin is among the highest compared to peers, indicating superior product pricing power or cost efficiency in production.